Rijk M C, van Schaik A, van Tongeren J H
Department of Gastroenterology, University Hospital Nijmegen, The Netherlands.
Scand J Gastroenterol Suppl. 1988;148:54-9. doi: 10.3109/00365528809101550.
Time-related urinary excretion and faecal excretion of 5-ASA and acetyl-5-ASA were measured in eight healthy volunteers after a single oral dose of the azo compounds sulphasalazine and olsalazine, the slow release compounds Pentasa, Asacol and Salofalk, and plain 5-ASA. After ingestion of both azo compounds and slow-release compounds, urinary excretion of 5-ASA was markedly delayed and reduced, and faecal excretion was enhanced. At all points of time, there was a significant, but not very marked difference in urinary excretion of 5-ASA after ingestion of the azo compounds and the slow-release compounds, in favour of the azo compounds. A significantly larger proportion of the ingested 5-ASA, moreover, was excreted in faeces after the intake of azo compounds as compared with slow-release compounds.
在八名健康志愿者单次口服偶氮化合物柳氮磺胺吡啶和奥沙拉嗪、缓释化合物颇得斯安、艾迪莎和莎尔福以及普通5-氨基水杨酸(5-ASA)后,对5-ASA和乙酰-5-ASA的时间相关尿排泄和粪便排泄进行了测量。摄入偶氮化合物和缓释化合物后,5-ASA的尿排泄明显延迟且减少,粪便排泄增加。在所有时间点,摄入偶氮化合物和缓释化合物后5-ASA的尿排泄存在显著但不太明显的差异,有利于偶氮化合物。此外,与缓释化合物相比,摄入偶氮化合物后,摄入的5-ASA有显著更大比例经粪便排泄。